Physician profile
Kim M Ross
NPI 1184600165
$55,737.89
in general payments reported to CMS, 2019-2025
42 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,981 · 2020: $931 · 2021: $2,085 · 2022: $3,061 · 2023: $13K · 2024: $11K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $9,905 · Food and Beverage: $9,051 · Travel and Lodging: $1,812 · Education: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,520.00 |
| Consulting Fee | $9,905.00 |
| Food and Beverage | $9,050.64 |
| Travel and Lodging | $1,811.67 |
| Education | $392.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27,720.28 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $12,136.84 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $4,734.27 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $1,191.27 | 2020-2025 | Nemluvio, Aklief, Twyneo |
| Abbvie INC. | $1,070.71 | 2019-2025 | Skyrizi, Botox, Ubrelvy |
| Lilly USA, LLC | $870.94 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $855.32 | 2020-2025 | Tremfya |
| Ucb, INC. | $823.55 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $605.47 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Allergan, INC. | $576.32 | 2019-2022 | |
| Epi Health, LLC | $540.19 | 2019-2020 | |
| Promius Pharma LLC | $521.23 | 2019 | |
| Incyte Corporation | $487.90 | 2022-2025 | Opzelura |
| Pfizer INC. | $455.86 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $443.75 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.